Open access · CC-BY
via OpenAlex
Long‐term treatment of cancer‐prone germline PTEN mutant mice with low‐dose rapamycin extends lifespan and delays tumour development
Priyanka Tibarewal, Victoria Rathbone, Georgia Constantinou, Wayne P Pearce, Mahreen Adil, Zofia Varyova, Lisa K. Folkes, Alix Hampson, Gala Anastasia Electra Classen, Adriana Alves, Sara Carvalho, Cheryl L. Scudamore, Bart Vanhaesebroeck
The Journal of Pathology · 2022 · ▲ 20 citations
Abstract
PTEN is one of the most commonly inactivated tumour suppressor genes in sporadic cancer. Germline heterozygous PTEN gene alterations also underlie PTEN hamartoma tumour syndrome (PHTS), a rare human cancer-predisposition condition. A key feature of systemic PTEN deregulation is the inability to adequately dampen PI3-kinase (PI3K)/mTORC1 signalling. PI3K/mTORC1 pathway inhibitors such as mTOR(definition)-inhibiting drug studied for extending healthspan and lifespan." style="text-decoration:underline dotted; text-underline-offset:2px; cursor:help;">rapamycin(definition) are therefore expected to neutralise the impact of PTEN loss, rendering this a more druggable context compared with those of other tumour suppressor pathways such as loss of TP53. However, this has not been explored in cancer prevention in a model of germline cancer predisposition, such as PHTS. Clinical trials of short-term treatment with rapamycin have recently been initiated for PHTS, focusing on cognition and colon polyposis. Here, we administered a low dose of rapamycin from the age of 6 weeks onwards to mice with heterozygous germline Pten loss, a mouse model that recapitulates most characteristics of human PHTS. Rapamycin was well tolerated and led to a highly significant improvement of survival in both male and female mice. This was accompanied by a delay in, but not full blockade of, the development of a range of proliferative lesions, including gastro-intestinal and thyroid tumours and endometrial hyperplasia, with no impact on mammary and prostate tumours, and no effect on brain overgrowth. Our data indicate that rapamycin may have cancer prevention potential in human PHTS. This might also be the case for sporadic cancers in which genetic PI3K pathway activation is an early event in tumour development, such as endometrial cancer and some breast cancers. To the best of our knowledge, this is the first report of a long-term treatment of a germline cancer predisposition model with a PI3K/mTOR pathway inhibitor. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1002/path.6009
- Canonical
- link ↗
- Fetched
- 2026-10-07 MST
Cite this
APA
Tibarewal, P., Rathbone, V., Constantinou, G., Pearce, W.P., Adil, M., Varyova, Z., Folkes, L.K., Hampson, A., Classen, G.A.E., Alves, A., Carvalho, S., Scudamore, C.L., & Vanhaesebroeck, B. (2022). Long‐term treatment of cancer‐prone germline PTEN mutant mice with low‐dose rapamycin extends lifespan and delays tumour development. <em>The Journal of Pathology</em>. https://doi.org/10.1002/path.6009
Vancouver
Tibarewal P, Rathbone V, Constantinou G, Pearce WP, Adil M, Varyova Z, et al. Long‐term treatment of cancer‐prone germline PTEN mutant mice with low‐dose rapamycin extends lifespan and delays tumour development. The Journal of Pathology. 2022. doi:10.1002/path.6009.
BibTeX
@article{priyanka2022Longte,
title = {Long‐term treatment of cancer‐prone germline PTEN mutant mice with low‐dose rapamycin extends lifespan and delays tumour development},
author = {Priyanka Tibarewal and Victoria Rathbone and Georgia Constantinou and Wayne P Pearce and Mahreen Adil and Zofia Varyova and Lisa K. Folkes and Alix Hampson and Gala Anastasia Electra Classen and Adriana Alves and Sara Carvalho and Cheryl L. Scudamore and Bart Vanhaesebroeck},
journal = {The Journal of Pathology},
year = {2022},
doi = {10.1002/path.6009},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Figshare 2018
Preprint
Age-related mTOR in ovarian and endometrial cancers
Molecular Biology and Evolution 2021
Open access · CC-BY
Conservation of Aging and Cancer Epigenetic Signatures across Human and Mouse
Photochemical & Photobiological Sciences 2025
Open access · CC-BY
Oral nicotinamide mononucleotide (NMN) increases tissue NAD+ content in mice but neither NMN nor Polypodium leucotomos protect against UVR-induced skin cancer
Journal of Taibah University Medical Sciences 2026
Open access · OA
Impact of aging on the tumor microenvironment in oral cancer: Mechanisms and therapeutic perspectives
biorxiv 2024
Preprint · CC-BY
Human Brain Mapping of Homotopic Functional Affinity
Nature 2009
Open access · OA